GenSight Biologics S A : Convening notice – 2023 General Meeting
CONVENING OF THE COMBINED GENERAL MEETING ON JUNE 21, 2023 GENSIGHT BIOLOGICS A French Société Anonyme ... | May 31, 2023
Source: marketscreener.com
📰 Early Access Authorisation News
Early Access Authorisation News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Early Access Authorisation. Real-time updates on events, politics, business and more.
Biophytis has Filed with the French National Authority for Health (HAS) ...
Biophytis has Filed with the French National Authority for Health (HAS) ...
Source: pr-inside.com
Biophytis has Filed with the French National Authority for Health an Application for Early Access Authorisation for Sarconeos in the Treatment of Severe Forms of COVID-19
PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 26, 2023 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the
Source: finanznachrichten.de
Biophytis has filed with the French National Authority for Health (HAS) an application for Early Ac
Biophytis / Key word(s): Miscellaneous Biophytis has filed with the French National Authority for Health (HAS) an application for Early Access Authorisation (EAA) for Sarconeos (BIO101) in the treatment of severe forms of COVID-1 26-May-2023 / 08:00 CET/CEST Biophytis has filed with the French National Authorit...
Source: pharmiweb.com
ORPHELIA Pharma Selects Tanner Pharma Group to Initiate Named Patient Program for KIMOZO (temozolomide) in European Countries
ORPHELIA Pharma, a French biopharmaceutical company dedicated to the development and marketing of pediatric and orphan medicines, and Tanner Pharma Group, a global provider of integrated specialty
Source: finanznachrichten.de
GenSight Biologics S.A.: GenSight Biologics Reports Full Year 2022 Consolidated Financial Results
Efforts to reduce cash burn in 2023 while securing LUMEVOQ manufacturing and preparing for commercial launch in Europe in H1 2024 PPQ campaign to start early May 2023 with results expected
United Kingdom United States Clothilde Caillet Gensight Biologics Guillaume Van Renterghem James Palmer
Source: finanznachrichten.de
GenSight Biologics S.A.: GenSight Biologics Provides Update on LUMEVOQ Manufacturing and Commercialization Timelines
PPQ campaign to start early May 2023 (previously end of March) with results expected in Q3 2023 EMA CHMP opinion now expected in Q1 2024 (previously September 2023) Regulatory News: GenSight
United States France General Dennis Riedl Clothilde Caillet James Palmer Gensight Biologics Euronext
Source: finanznachrichten.de